Who Owns Anika Company?

Anika Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Anika Therapeutics?

Understanding Anika Therapeutics' ownership is key to its strategic direction and accountability. A recent 27.42% stock price drop on July 30, 2025, highlights how ownership reacts to corporate developments, impacting market valuation.

Anika Therapeutics, a medical technology firm founded in 1992, specializes in hyaluronic acid-based solutions for orthopedic and traumatic conditions. Its focus spans pain management, tissue regeneration, and wound healing, aiming to innovate therapies for patients.

Who owns Anika Therapeutics?

As of August 2025, Anika Therapeutics is publicly traded on NASDAQ (ANIK). Its market capitalization hovers between $118 million and $127 million, with approximately 14.4 million shares outstanding. The company reported trailing twelve-month revenue of $93.1 million as of June 30, 2025, and held the #1 U.S. OA Pain market share as of March 31, 2025. This analysis will explore Anika's ownership journey, from its inception to current stakeholders, including founders, major investors, and public shareholders.

Anika Therapeutics, Inc. was established in 1992 as a spin-off from MedChem Products, Inc. The company's foundation was built upon hyaluronic acid (HA) technology, which positioned it as a key player in the viscosupplementation market for osteoarthritis.

Founding Details

Specific individual founders and their initial equity stakes at the company's inception are not readily available in public records.

Early Investment Landscape

Information regarding early backers, angel investors, or friends and family who acquired stakes during the initial phase is not extensively publicized.

Proprietary Technology

The company's early development centered on commercializing HA-based products, establishing its leadership in a specific medical market.

Early Corporate Agreements

Details on early agreements such as vesting schedules, buy-sell clauses, or founder exits are not widely disclosed.

Market Position

The company quickly became a recognized leader in its niche, leveraging its specialized technology for therapeutic applications.

Company Genesis

The company's origin as a spin-off indicates a strategic divestiture or creation of a new entity from an existing business structure.

The early history of Anika company ownership is marked by its incorporation in 1992, emerging from MedChem Products, Inc. with a focus on hyaluronic acid technology. While the precise details of its founders and their initial equity distribution are not publicly documented, the company's strategic direction was clear: to develop and commercialize HA-based products. This focus allowed Anika to establish itself as a leader in the viscosupplementation market for osteoarthritis. Understanding the Growth Strategy of Anika provides context for its early development and market penetration. Information regarding early investors, seed funding rounds, or specific shareholder agreements from this period remains largely private, making it challenging to pinpoint exact early ownership structures or individual Anika company stakeholders at its inception.

Key Aspects of Early Ownership

While specific founder details are scarce, the company's early trajectory was defined by its technological foundation and market entry.

• Incorporated in 1992 as a spin-off.
• Leveraged hyaluronic acid (HA) technology.
• Focused on viscosupplementation for osteoarthritis.
• Early ownership and investor details are not publicly detailed.

Anika SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Anika Therapeutics became a publicly traded company on April 29, 1993, marking the beginning of its evolving ownership landscape. This transition to public ownership has shaped its shareholder base and governance structure over the years.

As of August 18, 2025, Anika Therapeutics has a substantial base of 281 institutional owners and shareholders who have reported their holdings to the SEC. These entities collectively possess 13,841,935 shares, representing approximately 96.00% of the total institutional shares. This significant institutional stake underscores the influence of major investment firms on the company's direction. In May 2025, institutional investors held a commanding 88.80% of Anika's shares, with insiders holding 3.32%. Mutual funds, a key segment of institutional ownership, accounted for 36.22% of shares in May 2025, showing a slight decrease from 36.72% in April 2025. Understanding who owns Anika is crucial for grasping its corporate structure and the dynamics of its shareholder base.

Key Ownership Insights

Anika's ownership is heavily concentrated among institutional investors, indicating a strong reliance on large investment firms for capital and strategic guidance.

• Anika Therapeutics is a publicly traded company, first going public in 1993.
• As of August 18, 2025, 281 institutional owners have filed with the SEC.
• Institutional investors held approximately 88.80% of shares in May 2025.
• Insiders held a 3.32% stake in May 2025.
• The company's Mission, Vision & Core Values of Anika are likely influenced by its broad shareholder base.

Anika PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The board of directors at Anika Therapeutics is instrumental in the company's governance. As of May 2024, the board comprised ten members, including new appointments Joseph Capper and William Jellison. Following the 2024 Annual Meeting, the board is slated to reduce to nine directors, with a strong emphasis on independence, expecting eight to be independent. John B. Henneman III holds the position of Chairman of the Board.

Anika Therapeutics employs a straightforward one-share-one-vote system, meaning each share of common stock carries a single vote for director elections and other corporate matters. There is no evidence of dual-class share structures or preferential voting rights. However, significant institutional investors can wield considerable influence. For instance, Caligan Partners LP has a cooperation agreement with Anika, stipulating their votes align with the board's recommendations until shortly before the 2025 annual meeting. This arrangement, alongside regular meetings with the Capital Allocation Committee and management, underscores the impact major shareholders have on strategic decisions, providing insight into Revenue Streams & Business Model of Anika.

Anika Company's Shareholder Influence

Anika Therapeutics operates with a standard voting structure. Major shareholders can significantly impact corporate decisions through agreements and active participation.

• One-share-one-vote policy
• Caligan Partners LP cooperation agreement
• Influence of institutional investors
• Board oversight and strategic direction

Anika Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the Anika company ownership structure has seen notable shifts, reflecting strategic realignments and market responses. These changes impact how the Anika corporation owner landscape is perceived and managed.

The company's recent performance has been significantly influenced by clinical trial outcomes and subsequent strategic decisions. The failure of the Hyalofast pivotal trial to meet its primary endpoints in July 2025 led to a substantial stock decline, prompting investigations into the company's disclosures. This period also saw a restructuring of leadership and operational responsibilities, with a clear move to streamline operations and focus on key product areas.

Strategic Realignment

Anika is concentrating on OA Pain Management and Regenerative Solutions. This involves divesting non-core assets like Arthrosurface and Parcus Medical.

Financial Maneuvers

A $40 million share repurchase program was initiated in May 2024. An initial $15 million portion was completed early in March 2025.

Leadership and Operational Changes

Steve Griffin took over as CFO in June 2024. The COO position was eliminated in April 2025, with operational duties absorbed by the finance department.

Market Impact and Scrutiny

Market capitalization fell by 68.91% in the year ending August 19, 2025. Investor litigation is underway following trial setbacks, reflecting increased scrutiny in the sector. For more on the company's journey, see the Brief History of Anika.

Anika Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔